X @The Wall Street Journal
The Wall Street Journal·2026-02-13 07:01
The pharma major said that phase 3 trials showed Vanrafia slowed the decline in kidney function for adults with progressive autoimmune kidney disease, IgA nephropathy. https://t.co/rzLmDl5mcZ ...